| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 1.23% |
| NAV | ₹182.74 (06 Aug 2020) |
|---|---|
| Fund Started | 01 Jan 2013 |
| Fund Size | ₹1,154 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 10.2% |
| Cipla Ltd. | Healthcare | Equity | 10.0% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 9.4% |
| Lupin Ltd. | Healthcare | Equity | 9.1% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 7.5% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 7.1% |
| Alembic Pharmaceuticals Ltd. | Healthcare | Equity | 4.7% |
| Abbott India Ltd. | Healthcare | Equity | 4.1% |
| Biocon Ltd. | Healthcare | Equity | 3.6% |
| Strides Pharma Science Ltd. | Healthcare | Equity | 3.5% |
SBI Healthcare Opportunities Fund Direct Plan Growth is a Equity Mutual Fund Scheme launched by SBI Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Tanmaya Desai is the Current Fund Manager of SBI Healthcare Opportunities Fund Direct Plan Growth fund.The fund currently has an Asset Under Management(AUM) of ₹1,154 Cr and the Latest NAV as of 06 Aug 2020 is ₹182.74.
The SBI Healthcare Opportunities Fund Direct Plan Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 0.50% if redeemed within 15 days
To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy. There are five sub-funds dedicated to specific investment themes viz. Information Technology,Pharmaceuticals, FMCG, Contrarian (investment in stocks currently out of favour) and Emerging Businesses.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.